Diabetic Retinopathy Overview

Diabetic retinopathy (DR) is a micro vascular disorder occurring due to long term effects of diabetes, leading to vision-threatening damage to the retina, eventually leading to blindness. Diabetic retinopathy affects people with diagnosed or undiagnosed diabetes mellitus.

“Diabetic Retinopathy Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetic Retinopathy Market.

The Diabetic Retinopathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Diabetic Retinopathy Pipeline Report:

• Companies across the globe are diligently working toward developing novel Diabetic Retinopathy treatment therapies with a considerable amount of success over the years. Diabetic Retinopathy Key players such as – Opthea Limited, REGENXBIO Inc., Kodiak Sciences Inc., Novartis, Adverum Biotechnologies, Glycadia, Applied Therapeutics, EyeGene, AptaBio Therapeutics, MingSight Pharmaceuticals, Boehringer Ingelheim, OccuRx, Oxurion, Adverum Biotechnologies, Apexian Pharmaceuticals, Inc., Hoffman-La-Roche, and others, are developing therapies for the Diabetic Retinopathy treatment 
• Diabetic Retinopathy Emerging therapies such as – OPT-302, RGX-314, KSI-301, RTH258, ADVM-022, Brolucizumab, GLY-230, AT 003, EG-Mirotin, APX-1004, MS-553, BI 764524, OCX 063, THR-687, ADVM-022, APX3330, RG7774, and others are expected to have a significant impact on the Diabetic Retinopathy market in the coming years.   
• In May 2022, EyePoint Pharmaceuticals announced the EYP-1901 license to Betta Pharmaceuticals, to develop and commercialize EYP-1901 in China, Hong Kong, Macau, and Taiwan. EyePoint retains all rights for EYP-1901 in the rest of the world and expands its exclusive rights to local delivery of vorolanib for the treatment of all ophthalmic diseases, including diabetic macular edema (DME). Phase 2 clinical trial for EYP-1901 in non-proliferative diabetic retinopathy (NPDR) is expected to initiate in 2H 2022
• In April 2022, Ocuphire Pharma presented masked safety data from the ongoing ZETA-1 Phase 2b trial of oral APX3330 for the treatment of diabetic retinopathy. The results show a favorable ophthalmic and systemic safety and tolerability profile, consistent with 11 prior safety trials of APX3330 in non-ophthalmic indications. The company expects to report top-line results from the ZETA-1 trial in the second half of 2022
• In January 2022, Ocuphire Pharma entered into an agreement with Apexian Pharmaceuticals, Inc., granting Ocuphire an exclusive worldwide sublicense to Apexian’s Ref-1 Inhibitor program, including its lead drug candidate APX3330, for all ophthalmic and diabetic indications
• REGENXBIO announced additional positive interim data from the ongoing Phase II ALTITUDE trial of RGX-314 for the treatment of diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME) using in-office suprachoroidal delivery

Route of Administration

Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Intravenous

Molecule Type

Products have been categorized under various Molecule types, such as

• Small molecule
• Peptide
• Antibiotics 

Diabetic Retinopathy Pipeline Therapeutics Assessment

• Diabetic Retinopathy Assessment by Product Type
• Diabetic Retinopathy By Stage and Product Type
• Diabetic Retinopathy Assessment by Route of Administration
• Diabetic Retinopathy By Stage and Route of Administration
• Diabetic Retinopathy Assessment by Molecule Type
• Diabetic Retinopathy by Stage and Molecule Type

DelveInsight’s Diabetic Retinopathy Report covers around 60+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Diabetic Retinopathy Therapeutics Market include:

Key companies developing therapies for Diabetic Retinopathy are – Kodiak Sciences, Novartis, Bayer, RemeGen, Aerpio Therapeutics, Hoffman-La-Roche, Regenxbio Inc., Apexian Pharmaceuticals, Inc., Ocuphire Pharma, Inc., Adverum Biotechnologies, Oxurion, MingSight Relin Pharmaceuticals, Boehringer Ingelheim, NovaGo Therapeutics, RIBOMIC, Retinset SL, PYC Therapeutics, PharmAbcine, Palatin Technologies, LUYE PHARMA, Curacle, BONAC corporation, AptaBio Therapeutics, Ascentage Pharma, EyeGene, Applied Therapeutics, Foresee Pharmaceuticals, Glycadia, Everglades Biopharma, Novelty Nobility Inc, Noveome Biotherapeutics, Shanghai Henlius Biotech, EyePoint Pharmaceuticals, and others.

Emerging Diabetic Retinopathy Drugs Under Different Phases of Clinical Development Include:

• OPT-302: Opthea Limited
• RGX-314: REGENXBIO Inc.
• KSI-301: Kodiak Sciences Inc.
• RTH258: Novartis
• ADVM-022: Adverum Biotechnologies
• Brolucizumab: Novartis
• GLY-230: Glycadia
• AT 003: Applied Therapeutics
• EG-Mirotin: EyeGene
• APX-1004: AptaBio Therapeutics
• MS-553: MingSight Pharmaceuticals
• BI 764524: Boehringer Ingelheim
• OCX 063: OccuRx
• THR-687: Oxurion
• ADVM-022: Adverum Biotechnologies
• APX3330: Apexian Pharmaceuticals, Inc.
• RG7774: Hoffman-La-Roche

Get a Free Sample PDF Report to know more about Diabetic Retinopathy Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/diabetic-retinopathy-pipeline-insight

Diabetic Retinopathy Pipeline Analysis:

The Diabetic Retinopathy pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Retinopathy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Retinopathy Treatment.
• Diabetic Retinopathy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Diabetic Retinopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Retinopathy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Diabetic Retinopathy product details are provided in the report. Download the Diabetic Retinopathy pipeline report to learn more about the emerging Diabetic Retinopathy therapies

Diabetic Retinopathy Pipeline Market Strengths

• Different possible pathways have been extensively studied which could be responsible for the disease. Therefore a better understanding has been obtained through years of thorough research and development

Diabetic Retinopathy Pipeline Market Opportunities

• A large patient pool allows companies to make cost effective drugs and realize substantial gains

Scope of Diabetic Retinopathy Pipeline Drug Insight    

• Coverage: Global
• Key Diabetic Retinopathy Companies: Opthea Limited, REGENXBIO Inc., Kodiak Sciences Inc., Novartis, Adverum Biotechnologies, Glycadia, Applied Therapeutics, EyeGene, AptaBio Therapeutics, MingSight Pharmaceuticals, Boehringer Ingelheim, OccuRx, Oxurion, Adverum Biotechnologies, Apexian Pharmaceuticals, Inc., Hoffman-La-Roche, and others
• Key Diabetic Retinopathy Therapies: OPT-302, RGX-314, KSI-301, RTH258, ADVM-022, Brolucizumab, GLY-230, AT 003, EG-Mirotin, APX-1004, MS-553, BI 764524, OCX 063, THR-687, ADVM-022, APX3330, RG7774, and others
• Diabetic Retinopathy Therapeutic Assessment: Diabetic Retinopathy current marketed and Diabetic Retinopathy emerging therapies
• Diabetic Retinopathy Market Dynamics: Diabetic Retinopathy market drivers and Diabetic Retinopathy market barriers 

Request for Sample PDF Report for Diabetic Retinopathy Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Diabetic Retinopathy drugs and therapies

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting